Drugs / IFN-α
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07449286 | Mar → Dec 2026 expected | acute myeloid leukemia, myelodysplastic syndrome | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN-α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449286 ↗ |
| Route | Subcutaneous | “subcutaneously injected twice a week.” NCT07449286 ↗ |